Ventricular tachycardia ablation in structural heart disease with LV-EF>35%: impact of cardiomyopathy type on outcomes and ICD therapy

14 April 2026 (08:00 - 14:45)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Associate Professor Angeliki Darma

Heart and Diabetes Center NRW, Bad Oeynhausen (Germany)

188 More presentations in this session

Presentation thumbnail

Comparison of ECG findings between young patients with cryptogenic ischemic stroke and stroke-free control subjects

Doctor J. Uutela (Jyvaskyla, FI)

Presentation thumbnail

A wearable SCG-based approach for early, low-cost screening of valvular heart disease

Doctor V. Pergola (Naples, IT)

Presentation thumbnail

Intraoperative assessment of cardiac parasympathetic tone using short-term HRV metrics before and after atropine administration: a pilot study

Doctor B. Hrymniak (Wroclaw, PL)

Presentation thumbnail

Arrhythmia phenotypes in hair-loss therapies: insights from minoxidil and finasteride reports in eudravigilance

Doctor Y. Shhab (Bucharest, RO)

Presentation thumbnail

Arrhythmias and device therapy in HFpEF: Insights from a real-world hospital cohort

Ms A. Bondoc (Timisoara, RO)

Abstract Slides Video

Access the full session

Session thumbnail

Poster session (3): mechanisms and management of arrhythmias

The Event

Event poster

EHRA 2026

14 April 2026 08:00 CET

You may be interested in

Congress Presentation

Catheter ablation of sustained ventricular tachycardia in patients with structural heart disease and mildly reduced or preserved ejection fraction: results of the Preserved-AVT multicenter registry

Congress Session

Meet the Experts: the role of ventricular tachycardia ablation in structural heart disease

Congress Presentation

Case 1 - first choice treatment: antiarrhythmic drugs or catheter ablation?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources